Details of Disease

General Information of Disease (ID: DISTBY9Z)

Disease Name Tumour
Disease Class 2A00-2F9Z: Solid tumour/cancer
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISTBY9Z: Tumour
ICD Code
ICD-11
ICD-11: 2A00-2F9Z
ICD-10
ICD-10: C00-D48
ICD-9
ICD-9: 140-199, 210-229
Expand ICD-9
140,141,142,143,144,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000
Disease Identifiers
MONDO ID
MONDO_0005070
MESH ID
D009369
UMLS CUI
C0027651
MedGen ID
10294
HPO ID
HP:0002664
SNOMED CT ID
108369006

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 2 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Doxorubicin DMVP5YE Approved Small molecular drug [1]
Fluorouracil DMUM7HZ Approved Small molecular drug [1]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Fenretinide DMRD5SP Phase 3 Small molecular drug [2]
4SCAR-GD2 DMEGSU5 Phase 1/2 CAR T Cell Therapy [3]
Anti-mesothelin CAR T Cells DM5BIM1 Phase 1 CAR T Cell Therapy [4]
CDX-0158 DM9RONX Phase 1 NA [5]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Cantide + Cisplatin DM9IG2P Investigative Combination drug [1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT02992210) Study on GD2 Positive Solid Tumors by 4SCAR-GD2
4 ClinicalTrials.gov (NCT02930993) Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)